ClinicalTrials.gg
Not yet recruitingNCT07776041Updated Aug 20, 2026

A Study of SYH2092 Injection in Healthy Participants

A Phase 1 interventional study of SYH2092 Injection and Placebo in Overweight or Obesity, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 188 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.

Planned enrollment
134th of 169
46 · median 180
Started
2026
with 40 others
Phase 1
33 of 188
15 open now
Primary completion
2027-02
later than 14 of 73 live
Registered
178th of 188
by date

Among the 188 studies in Obesity with a site in Australia, this one is the 134th largest by planned enrollment of the 169 interventional ones that give a count, is one of 41 that started in 2026, is one of 33 in phase 1, reaches primary completion later than 14 of the 73 other live ones, and was the 178th registered.

Obesity

11,556 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

56 of the 188 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Obesity with a site in Australia, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of SYH2092 Injection in healthy participants

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,556 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

This study's planned enrollment of 46 is below the median of 67 across 9,027 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd. is the lead sponsor of 42 studies on the registry; 41 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand the content, process and possible adverse drug reactions (ADRs) of the study before the study, and voluntarily sign the ICF;
  2. At Screening, aged 18 to 60 years (inclusive, based on the date of signing the ICF), including both males and females;
  3. At Screening, body weight ≥ 50 kg with a (BMI) of 18 to 35 kg/m²
  4. Body weight change ≤ 5% within 3 months prior to Screening (including the Screening Period) (based on participant self-report);
  5. Participants (including their partners) have no birth plan from signing the ICF until 6 months after the last dose, and agree to use highly effective measures as stipulated in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected allergy to amylin receptor agonists or any component of the product; or those with an allergic constitution (allergy to multiple drugs and foods);
  2. abnormal results in vital signs, physical examination, laboratory tests, or , as judged by the Investigator, that render the participant unsuitable for the study. The following conditions do not lead to exclusion: (1) TG ≤ 3.42 mmol/L, TC ≤ 7.5 mmol/L, HDL-C abnormal; (2) (ALT) \< 1.5 × (ULN), aspartate aminotransferase (AST) \< 1.5 × ULN, or total \<1.5 × ULN;
  3. ≥ 6.5% during Screening Period, or fasting glucose \< 3.9 mmol/L or ≥ 7 mmol/L;
  4. Prolonged interval during Screening Period (≥ 450 ms for males; ≥ 460 ms for females; see Section 13.5 for calculation formula), history of risk factors for Torsades de Pointes (e.g., cardiac failure/cardiomyopathy, or family history of long QT syndrome);
  5. Positive for any of the following: surface antigen, virus antibody, antibody, or Treponema antibody.
  6. Significant history or clinical manifestation of any metabolic, dermatological, hepatic, renal, hematological, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, immune or psychiatric disorder that, in the opinion of the Investigator, may place the participant at increased risk or interfere with study assessments. This does not include: resolved childhood asthma; mild intermittent asthma; seasonal allergic rhinitis; eczema with no use of topical creams within 3 months prior to Screening; fully resolved gestational diabetes; or Gilbert's syndrome;
  7. Severe trauma or major surgery within 3 months prior to Screening, or plan to undergo surgery during the study; 8)History of (not including basal cell carcinoma [BCC], squamous cell carcinoma [SCC], or carcinoma in situ of the cervix); history of severe/major depressive/anxiety (not including history of mild/resolved depressive/anxiety, as judged by the Investigator); or epilepsy (not including a history of febrile seizures in childhood);

9) History of clinical gastric emptying abnormalities (e.g., gastric outlet obstruction) or severe chronic gastrointestinal diseases (e.g., inflammatory bowel disease, active ulcers); history of acute or chronic pancreatitis; or active/current gallbladder disease (e.g., symptomatic cholelithiasis, cholecystitis). This does not include a history of cholecystectomy for resolved gallbladder disease; 10) History of gastrointestinal surgery that may lead to malabsorption, or long-term use of drugs directly affecting gastrointestinal motility, or other therapies that affect gastrointestinal motility. Examples include: bariatric surgery or procedures (e.g., gastric banding), or use of glucagon-like peptide-1 (GLP-1) receptor agonist, glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, amylin receptor agonists, or drugs/products deemed by the Investigator to cause body weight changes and affect body weight assessment within 3 months prior to Screening (see Section 6.8 for details); This does not include appendectomy or uncomplicated hernia repair, which are permitted; 11) Presence of symptoms or signs of dermatitis or skin abnormalities (including tattoos) at or around the injection site (abdomen), or within 5 cm of the injection site; 12) Use of any prescription drugs within 14 days prior to dosing, or less than 5 half-lives have elapsed since the last use (whichever is longer), with the exception of hormonal used for contraceptive purposes as permitted under Section 13.1.2; Use of any over-the-counter (OTC) drugs (excluding topical medications such as creams, ointments, or eye drops), dietary supplements, or herbal medicines within 7 days prior to dosing, or less than 5 half-lives have elapsed since the last use (whichever is longer), except for short-term use of paracetamol and anti-inflammatory drugs within 7 days prior to dosing, at the Investigator's discretion; 13)Use of drugs that may affect glucose metabolism (e.g., systemic steroids, non-selective beta-blockers, monoamine oxidase inhibitors) within 1 month prior to Screening, or less than 5 half-lives have elapsed since the last use of such drugs (whichever is longer); 14) Average weekly alcohol consumption exceeding 21 units (males) or 14 units (females) within 3 months prior to Screening (1 unit ≈ 360 mL of beer with 5% alcohol content, or 45 mL of spirits with 40% alcohol content, or 150 mL of wine with 12% alcohol content), positive breath alcohol test, or inability to abstain from alcohol during the study; 15)Participants who smoked > 10 cigarettes/week or 2 cigarettes/day (or nicotine-equivalent, including e-cigarettes/vaping devices) within 3 months prior to Screening or who cannot stop using any nicotine products (including cigarettes, e-cigarettes/vaping devices, smokeless tobacco, and nicotine replacement therapy) during the study. A positive cotinine result, or the need for repeat testing, may be permitted at the Investigator's discretion; 16) Average daily consumption of excessive tea, coffee, and/or caffeine-containing beverages (more than 8 cups on average, 1 cup ≈ 250 mL) within 3 months prior to Screening, or inability to abstain during the study; 17) Strenuous exercise (e.g., weightlifting, sprinting, long-distance running, cycling, swimming, soccer) within 48 h prior to Screening; 18) History of drug abuse within 3 months prior to Screening, or positive drug abuse screening test. A positive drug abuse screening test result attributable to a documented medical history of prescribed medication may be permitted at the Investigator's discretion, following discussion with the Sponsor, provided the participant is not currently receiving such medication; 19) Has donated whole blood or had a loss of whole blood of more than 500 mL within the 30 days prior to Screening; has donated plasma (plasmapheresis) within 7 days prior to Screening; or has received a blood transfusion within one year prior to Screening; Participants with a history of needle phobia and blood phobia, difficulty in blood collection or intolerance to venipuncture blood collection; 21) Participants who had special dietary requirements and could not accept a uniform diet and rest. The following dietary requirements will be accommodated: dairy/lactose-free, gluten-free, gluten-free and lactose-free, halal, no pork and beef, no red meat, no seafood, pescatarian, standard, vegan, and vegetarian; 22) Females who are pregnant, lactating, or have a positive serum pregnancy test during the Screening Period; 23) Participation in any other clinical study of drugs or medical devices within 3 months or 5 half-lives prior to Screening (whichever is longer), or planned participation in a clinical study of other drugs or medical devices during this study; 24) Participants whom the Investigator judges to have other factors that make them unsuitable to participate in the trial.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    SYH2092 Injection

    Drug: SYH2092 Injection

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugSYH2092 Injection

    Conduct in accordance with the study protocol.

  • DrugPlacebo

    Conduct in accordance with the study protocol.

07

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as accessed by CTCAE v6.0

    Time frame: Screening period up to day 71

Secondary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: predose on day 1 to day 71

  2. Area under the concentration-time curve from time 0 to the last measurable time point (AUClast)

    Time frame: predose on day 1 to day 71

  3. Area under the concentration time curve from time 0 to infinity (AUCinf)

    Time frame: predose on day 1 to day 71

  4. Percent of AUC extrapolated to infinity (AUC_Extrap)

    Time frame: predose on day 1 to day 71

  5. Time to maximum concentration (Tmax)

    Time frame: predose on day 1 to day 71

  6. Elimination half-life (t1/2)

    Time frame: predose on day 1 to day 71

  7. Apparent volume of distribution (Vz/F)

    Time frame: predose on day 1 to day 71

  8. Apparent clearance (CL/F)

    Time frame: Predose on day 1 to day 71

  9. Mean change in plasma glucose from baseline

    Time frame: baseline up to day 71

  10. Mean change in insulin from baseline

    Time frame: baseline up to day 71

  11. Mean change in C-peptide from baseline

    Time frame: baseline up to day 71

  12. Mean change in glucagon from baseline

    Time frame: baseline up to day 71

  13. Mean change in HbA1c from baseline

    Time frame: baseline up to day 71

  14. Change in body weight from baseline

    Time frame: baseline up to day 71

  15. Change in waist circumference from baseline

    Time frame: baseline up to day 71

  16. Mean change in Total Cholesterol(TC) from baseline

    Time frame: baseline up to day 71

  17. Mean change in Triglycerides(TG) from baseline

    Time frame: baseline up to day 71

  18. Mean change in Low-Density Lipoprotein Cholesterol(LDLC) from baseline

    Time frame: baseline up to day 71

  19. Mean change in High-Density Lipoprotein Cholesterol(HDLC) from baseline

    Time frame: baseline up to day 71

  20. Incidence and titer of anti-drug antibody (ADA)

    Time frame: predose on day 1 to day 71

  21. Fridericia-corrected QT interval (QTcF)

    Baseline- and placebo-adjusted corrected QTcF

    Time frame: baseline up to day 8

08

Study locations

1 site
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Feb 2027, 4 months later.

Of 336 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 4 months is below that.

Counting every sponsor, half of 441 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2026
First posted
Aug 20, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Feb 9, 2027
CompletionEst.
Apr 20, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07776041
Responsible party
Sponsor
First posted
Aug 20, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Feb 9, 2027 (estimated)
Completion
Apr 20, 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

Clinical Trials Information Group NA officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion